Whalesbook
Anthem Biosciences: Navigating Market Headwinds with Resilient Margins
Anthem Biosciences Limited has reported its financial performance for the third quarter and nine months ended December 31, 2025, revealing a strategic recalibration in its growth outlook amidst prevailing market conditions.
📉 The Financial Deep Dive
The Numbers: For the nine months ended December 31, 2025, consolidated revenue stood at ₹1,513 crore, with the CRDMO business contributing ₹1,260 crore and specialty ingredients ₹254 crore. EBITDA reached ₹671 crore, reflecting a robust margin of 41.5%. This figure included ₹105 crore of other income, primarily from forex gains, RoDTEP, and financial income. Profit Before Tax (PBT) before exceptional items was ₹572 crore. An exceptional item of ₹25.4 crore was recognized due to the notification of new Labor Codes. Profit After Tax (PAT) was reported at ₹402 crore, yielding a PAT margin of 24.8%. This represents a year-on-year PAT growth from ₹369 crore in the previous year.
For the third quarter of FY26, consolidated revenue was ₹423 crore (CRDMO: ₹333 crore, Specialty: ₹90 crore). EBITDA for the quarter was ₹191 crore, with a margin of 41.8%, including ₹33.5 crore of other income. PBT before exceptional items was ₹156 crore, and PAT stood at ₹93 crore with a margin of 20.3%. Management noted that quarterly revenue performance was lower than Q3 FY25 due to a higher base, though margin improvements provided some offset.
The Quality: The company's ability to maintain high EBITDA margins (around 41.5-41.8%) is a significant positive, even with a slight dip in Q3 revenue. The contribution of other income, particularly forex gains and RoDTEP, bolstered EBITDA. The exceptional item related to labor codes is a one-off impact. The structural factors, including backward integration, are proving effective in enhancing material margins and reducing reliance on China for intermediates, a key strategic advantage. While specific cash flow figures are not detailed, the strong EBITDA suggests healthy operating cash generation capacity.
The Grill: While no direct analyst 'grill' was evident in the provided text, the management's downward revision of revenue guidance from ~20% to mid-teens (15-16%) indicates a necessary acknowledgement of market realities, specifically customer destocking amid global uncertainties. The reaffirmation of margin guidance, however, signals confidence in operational efficiencies and pricing power.
🚩 Risks & Outlook
Specific Risks: The primary risk highlighted is customer destocking and broader market uncertainties, which directly impact near-term revenue visibility. The recognition of an exceptional item due to new Labor Codes, while classified as one-off, points to potential ongoing adjustments in compliance costs. Execution risks associated with the ambitious ₹1,000 crore CAPEX for Unit-4, aimed at supporting growth over the next two years, will need careful monitoring.
The Forward View: Management anticipates a strong Q4 to round off the fiscal year, as is typical. The revised revenue guidance, while lower, still points to respectable growth. The company is strategically focusing on high-growth areas such as peptides, GLP-1, and biosimilars, and aims to onboard new large pharma customers. The planned CAPEX underscores a commitment to future capacity expansion and sustained growth. Management's confidence in achieving historical CAGRs for the next five years suggests a positive long-term strategic direction, despite short-term macro headwinds.